Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Hindered alignment in ultrashort, intense laser-induced fragmentation of O2.

Sen A, Sairam T, Sahu SR, Bapat B, Gopal R, Sharma V.

J Chem Phys. 2020 Jan 7;152(1):014302. doi: 10.1063/1.5130706.

PMID:
31914771
2.

Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.

Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, García-Foncillas J, Candrilli SD, Kaye JA.

Eur J Cancer Care (Engl). 2019 Dec 27:e13213. doi: 10.1111/ecc.13213. [Epub ahead of print]

PMID:
31883156
3.

Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients.

Savio AJ, Kamdar S, Jeyapala R, Olkhov-Mitsel E, Cuizon C, Finelli A, Zlotta AR, Toi A, Fleshner NE, van der Kwast T, Bapat B.

J Mol Diagn. 2020 Jan;22(1):30-39. doi: 10.1016/j.jmoldx.2019.08.003. Epub 2019 Oct 9.

PMID:
31605802
4.

An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients.

Jeyapala R, Kamdar S, Olkhov-Mitsel E, Savio AJ, Zhao F, Cuizon C, Liu RS, Zlotta A, Fleshner N, van der Kwast T, Bapat B.

Urol Oncol. 2020 Feb;38(2):39.e1-39.e9. doi: 10.1016/j.urolonc.2019.08.017. Epub 2019 Sep 24.

PMID:
31558364
5.

GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.

Jeyapala R, Savio AJ, Olkhov-Mitsel E, Kamdar S, Zhao F, Cuizon C, Liu RSC, Zlotta A, Fleshner N, van der Kwast T, Bapat B.

Eur Urol Oncol. 2019 May;2(3):231-238. doi: 10.1016/j.euo.2018.08.003. Epub 2018 Sep 1.

PMID:
31200836
6.

Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.

Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, Bristow RG, Downes M, Vesprini D, Liu S, Bapat B, Boutros PC.

J Natl Cancer Inst. 2019 Jun 4. pii: djz112. doi: 10.1093/jnci/djz112. [Epub ahead of print]

PMID:
31161221
7.

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.

Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B.

Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.

8.

epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer.

O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS.

JCO Precis Oncol. 2019;2019. doi: 10.1200/PO.18.00134. Epub 2019 Jan 14.

9.

Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance.

Zhao F, Vesprini D, Liu RSC, Olkhov-Mitsel E, Klotz LH, Loblaw A, Liu SK, Bapat B.

Urol Oncol. 2019 May;37(5):297.e9-297.e17. doi: 10.1016/j.urolonc.2019.01.031. Epub 2019 Feb 16.

PMID:
30777394
10.

Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

Goldberg H, Cheung DC, Chandrasekar T, Klaassen Z, Wallis CJD, Kulkarni GS, Sayyid R, Evans A, Masoomian M, Bapat B, van der Kwast T, Hamilton RJ, Zlotta A, Fleshner N.

Can Urol Assoc J. 2019 Jan 21:E292-E299. doi: 10.5489/cuaj.5595. [Epub ahead of print]

11.

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.

Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O'Reilly E, Kelly S, Cooper C; Movember Urine Biomarker Consortium, Brewer D, Perry AS, Clark J, Fleshner N, Bapat B.

Clin Epigenetics. 2018 Nov 23;10(1):147. doi: 10.1186/s13148-018-0575-z.

13.

Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Campbell PT, Li Y, Yang N, Zhou X, Dicks E, Mclaughlin JR, Parfrey PS.

BMC Cancer. 2018 Feb 6;18(1):155. doi: 10.1186/s12885-018-4026-1.

14.

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.

Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE, Bapat B.

J Urol. 2018 Jun;199(6):1475-1481. doi: 10.1016/j.juro.2017.12.006. Epub 2017 Dec 12.

PMID:
29246734
15.

Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population.

Zhu Y, Wang PP, Zhai G, Bapat B, Savas S, Woodrow JR, Sharma I, Li Y, Zhou X, Yang N, Campbell PT, Dicks E, Parfrey PS, Mclaughlin JR.

Br J Cancer. 2017 Sep 5;117(6):898-906. doi: 10.1038/bjc.2017.242. Epub 2017 Aug 1.

16.

Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.

Olkhov-Mitsel E, Siadat F, Kron K, Liu L, Savio AJ, Trachtenberg J, Fleshner N, van der Kwast T, Bapat B.

Oncol Lett. 2017 Jul;14(1):390-396. doi: 10.3892/ol.2017.6140. Epub 2017 May 9.

17.

Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.

PMID:
28376164
18.

Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer.

Savio AJ, Bapat B.

Epigenetics. 2017 Jun 3;12(6):441-448. doi: 10.1080/15592294.2017.1305527. Epub 2017 Mar 17.

19.

The dynamic DNA methylation landscape of the mutL homolog 1 shore is altered by MLH1-93G>A polymorphism in normal tissues and colorectal cancer.

Savio AJ, Mrkonjic M, Lemire M, Gallinger S, Knight JA, Bapat B.

Clin Epigenetics. 2017 Mar 9;9:26. doi: 10.1186/s13148-017-0326-6. eCollection 2017.

20.

Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, van Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B.

Transl Oncol. 2017 Apr;10(2):168-177. doi: 10.1016/j.tranon.2017.01.001. Epub 2017 Feb 3.

21.

Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B.

J Urol. 2017 Feb;197(2):335-341. doi: 10.1016/j.juro.2016.08.081. Epub 2016 Aug 18.

PMID:
27545574
22.

Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.

White-Al Habeeb NM, Garcia J, Fleshner N, Bapat B.

Prostate. 2016 Dec;76(16):1507-1518. doi: 10.1002/pros.23235. Epub 2016 Jul 12.

PMID:
27404348
23.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

24.

Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis.

Kamdar SN, Ho LT, Kron KJ, Isserlin R, van der Kwast T, Zlotta AR, Fleshner NE, Bader G, Bapat B.

Clin Epigenetics. 2016 Mar 15;8:32. doi: 10.1186/s13148-016-0195-4. eCollection 2016.

25.

Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients.

Savio AJ, Daftary D, Dicks E, Buchanan DD, Parfrey PS, Young JP, Weisenberger D, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B.

BMC Cancer. 2016 Feb 17;16:113. doi: 10.1186/s12885-016-2149-9.

26.

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B.

Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461579
27.

Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

Smyth EN, Bapat B, Ball DE, André T, Kaye JA.

Clin Ther. 2015 Jun 1;37(6):1301-16. doi: 10.1016/j.clinthera.2015.03.016. Epub 2015 Apr 20.

28.

Charge symmetric dissociation of doubly ionized N2 and CO molecules.

Pandey A, Bapat B, Shamasundar KR.

J Chem Phys. 2014 Jan 21;140(3):034319. doi: 10.1063/1.4861665.

PMID:
25669391
29.

Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history.

Weisenberger DJ, Levine AJ, Long TI, Buchanan DD, Walters R, Clendenning M, Rosty C, Joshi AD, Stern MC, LeMarchand L, Lindor NM, Daftary D, Gallinger S, Selander T, Bapat B, Newcomb PA, Campbell PT, Casey G, Ahnen DJ, Baron JA, Haile RW, Hopper JL, Young JP, Laird PW, Siegmund KD; Colon Cancer Family Registry.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):512-519. doi: 10.1158/1055-9965.EPI-14-1161. Epub 2015 Jan 13.

30.

Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.

van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH.

Mod Pathol. 2015 May;28(5):695-705. doi: 10.1038/modpathol.2014.154. Epub 2014 Nov 28.

31.

Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.

Savio AJ, Bapat B.

Methods Mol Biol. 2015;1238:103-24. doi: 10.1007/978-1-4939-1804-1_6. Review.

PMID:
25421657
32.

Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer.

White-Al Habeeb NM, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B.

Oncotarget. 2014 Sep 15;5(17):7858-69.

33.

FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.

Neuzillet Y, van Rhijn BW, Prigoda NL, Bapat B, Liu L, Bostrom PJ, Fleshner NE, Gallie BL, Zlotta AR, Jewett MA, van der Kwast TH.

Virchows Arch. 2014 Aug;465(2):207-13. doi: 10.1007/s00428-014-1596-4. Epub 2014 Jun 1.

PMID:
24880661
34.

Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids.

Olkhov-Mitsel E, Zdravic D, Kron K, van der Kwast T, Fleshner N, Bapat B.

Sci Rep. 2014 Mar 21;4:4432. doi: 10.1038/srep04432.

35.

Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.

Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M.

Nat Genet. 2014 Feb;46(2):107-115. doi: 10.1038/ng.2854. Epub 2013 Dec 22.

36.

Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.

Saraon P, Trudel D, Kron K, Dmitromanolakis A, Trachtenberg J, Bapat B, van der Kwast T, Jarvi KA, Diamandis EP.

Prostate. 2014 Apr;74(4):372-80. doi: 10.1002/pros.22758. Epub 2013 Dec 6.

PMID:
24311408
37.

Three body dissociation of CS2(2+) subsequent to various S(2p) Auger transitions.

Saha K, Banerjee SB, Bapat B.

J Chem Phys. 2013 Oct 28;139(16):164309. doi: 10.1063/1.4826468.

PMID:
24182031
38.

A combined electron-ion spectrometer for studying complete kinematics of molecular dissociation upon shell selective ionization.

Saha K, Banerjee SB, Bapat B.

Rev Sci Instrum. 2013 Jul;84(7):073101. doi: 10.1063/1.4811796.

PMID:
23902038
39.

Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.

Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, Bapat B.

Clin Cancer Res. 2013 Jul 1;19(13):3450-61. doi: 10.1158/1078-0432.CCR-12-3139. Epub 2013 Apr 2.

40.

Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers.

Olkhov-Mitsel E, Bapat B.

Cancer Med. 2012 Oct;1(2):237-60. doi: 10.1002/cam4.22. Epub 2012 Sep 14. Review.

41.

MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of healthy individuals.

Savio AJ, Lemire M, Mrkonjic M, Gallinger S, Zanke BW, Hudson TJ, Bapat B.

PLoS One. 2012;7(12):e51531. doi: 10.1371/journal.pone.0051531. Epub 2012 Dec 11.

42.

Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients.

Rawson JB, Sun Z, Dicks E, Daftary D, Parfrey PS, Green RC, Gallinger S, McLaughlin JR, Wang PP, Knight JA, Bapat B.

Nutr Cancer. 2012;64(7):919-28. doi: 10.1080/01635581.2012.711418. Epub 2012 Sep 11.

43.

Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR.

Eur Urol. 2013 Feb;63(2):379-85. doi: 10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2.

PMID:
22883484
44.

Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B.

Epigenetics. 2012 Sep;7(9):1037-45. Epub 2012 Aug 9.

45.

Lynch syndrome in a predominantly Afrocentric population: a clinicopathological and genetic study.

Plummer JM, Chin SN, Aronson M, Graham RP, Williams NP, Bapat B, Wharfe G, Pollett A, Gallinger S.

Can J Surg. 2012 Oct;55(5):294-300.

46.

Epigenetic biomarkers in colorectal cancer diagnostics.

Rawson JB, Bapat B.

Expert Rev Mol Diagn. 2012 Jun;12(5):499-509. doi: 10.1586/erm.12.39. Review.

PMID:
22702366
47.

Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.

Pasic MD, Olkhov E, Bapat B, Yousef GM.

Biol Chem. 2012 Apr;393(5):319-30. doi: 10.1515/hsz-2011-0273. Review.

PMID:
22505515
48.

Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.

Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T.

Clin Cancer Res. 2012 May 15;18(10):2896-904. doi: 10.1158/1078-0432.CCR-11-2901. Epub 2012 Mar 27.

49.

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.

van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR.

BJU Int. 2012 Oct;110(8):1169-76. doi: 10.1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27.

50.

Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA, Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR, Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Jenkins MA.

J Clin Oncol. 2012 Mar 20;30(9):958-64. doi: 10.1200/JCO.2011.39.5590. Epub 2012 Feb 13.

Supplemental Content

Support Center